NDAINTRACAVITARY, INTRAVENOUS, INTRAVESICALPOWDER
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
TEPADINA (thiotepa) by Adienne Pharma and Biotech is alkylating activity [moa]. First approved in 2017.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEPADINA (thiotepa) is an alkylating agent administered via intracavitary, intravenous, or intravesical routes as a powder formulation. It works through alkylating activity to disrupt DNA in cancer cells. The drug is indicated for multiple oncology applications across different anatomical routes of delivery.
Peak10.9 years to LOE
Product is at peak commercial stage with stable market position; core team focused on market maintenance and specialized indication penetration.
Mechanism of Action
Alkylating Activity
Pharmacologic Class:
Alkylating Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Started Dec 2006
1 enrolled
Graft Versus Host DiseaseLeukemiaMyelodysplastic Syndromes
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
Started Mar 2005
37 enrolled
Lymphoma
Career Relevance
Working on TEPADINA offers exposure to specialized oncology commercialization in a niche market with minimal competitive pressure and stable demand. Career advancement opportunities center on market penetration, physician engagement, and market access strategy in a mature, monopolistic product environment.
Worked on TEPADINA at Adienne Pharma and Biotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.